Prognostic significance of the proliferative activity in neuroblastoma

American Journal of Pathology

Volumn 150, Issue 1, 1997, Pages 133-145

  Rudolph, Pierre ^a,c   Lappe, Thomas ^a   Hero, Barbara ^a   Berthold, Frank ^a   Parwaresch, Reza ^a   Harms, Dieter ^b   Schmidt, Dietmar ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Department of General Pathology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADOLESCENT; AGE; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NEWBORN; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CELL DIVISION; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; NEUROBLASTOMA; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031012927     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look AT, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y, Voûte PA: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11:1466-1477
2. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma. Cancer 1971, 27:374-378
3. Berthold F, Kassenbohmer R, Zieschang J: Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediatr Hematol Oncol 1994, 16:107-115
4. Berthold, F. Overview: biology of neuroblastoma. Neuroblastoma: Tumor Biology and Therapy. Edited by C Pochedly. Boca Raton, FL, CRC Press, 1990, pp 1-27
5. Beckwith M, Ruscetti FW, Sing GK, Urba WJ, Longo DL: Anti-IgM induces transforming growth factor-β sensitivity in a human B-lymphoma cell line: inhibition of growth is associated with a downregulation of mutant p53. Blood 1995, 85:2461-2470
6. Shimada H, Chatten J, Newton WAJ, Sachs N, Hamoud AB, Chiba T, Misugi K: Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984, 73:405-416
7. Hughes M, Marsden HB, Palmer MK: Histologie patterns of neuroblastoma related to prognosis and clinical staging. Cancer 1974, 34:1706-1711
8. Joshi VV, Cantor AB, Altshuler G, Larkin EW, Neill JSA, Shuster JJ, Holbrook CT, Hayes FA, Nitschke R, Duncan MH, Shochat SJ, Talbert J, Smith EI, Castleberry RP: Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. Cancer 1992, 69:2197-2211
9. Chatten J, Shimada H, Sather HN, Wong KY, Siegel SE, Hammond GD: Prognostic value of histopathology in advanced neuroblastoma: a report from the Childrens Cancer Study Group. Hum Pathol 1988, 19:1187-1198
10. Hedborg F, Bjelfman C, Sparén P, Sandsted B, Pahlman S: Biochemical evidence for a mature phenotype in morphologically poorly differentiated neuroblastomas with a favourable outcome. Eur J Cancer 1995, 31A:435-443
11. Joshi VV, Cantor AB, Altshuler G, Larkin EW, Neill JSA, Shuster JJ, Holbrook CT, Hayes FA, Castleberry RP: Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. Cancer 1992, 69:2183-2196
12. Bove KE, McAdams J: Composite ganglioneuroblastoma: an assessment of the significance of histological maturation in neuroblastoma diagnosed beyond infancy. Arch Pathol Lab Med 1981, 105:325-330
13. Ambros IM, Ambros PF: Schwann cells in neuroblastoma. Eur J Cancer 1995, 31A:429-434
14. Ambros PF, Ambros IM, Strehl S, Bauer S, Luegmayr A, Kovar H, Ladenstein R, Fink F-M, Horcher E, Printz G, Mutz I, Schilling F, Urban C, Gadner H: Regression and progression in neuroblastoma: does genetics predict tumour behaviour? Eur J Cancer 1995, 31A:510-515
15. Aoyama C, Qualman SJ, Regan M, Shimada H: Histopathologic features of composite ganglioneuroblastoma. Cancer 1990, 65:255-264
16. Wirnsberger GH, Becker H, Ziervogel K, Höfler H: Diagnostic immunohistochemistry of neuroblastic tumors. Am J Surg Pathol 1992, 16:49-57
17. Ladenstein R, Urban C, Gadner H, Fink FM, Zoubek A, Emminger W, Grienberger H, Schmitt K, Ambros PF, Ambros IM, Horcher E, Amann G, Höfler G, Kerbel R, Mutz I: First experience with prognostic factors in unselected neuroblastoma patients: the Austrian neuroblastoma 87 study. Eur J Cancer 1995, 31A:637-641
18. Dominici C, Nicotra MR, Digiesi G, McDowell H, Alemà S, Padula A, Gargano N, Donfrancesco A, Castello MA, Natali PG: Immunohistochemical detection of high-af- finity nerve growth factor receptor in neuroblastoma. Eur J Cancer 1995, 31A:444-446
19. Brodeur GM: Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 1995, 31A:505-510
20. Gansler T, Chatten J, Varello M, Bunin GR, Atkinson B: Flow cytometric DMA analysis of neuroblastoma: correlation with histology and clinical outcome. Cancer 1986, 58:2453-2458
21. Huddart SN, Muir KR, Parkes SE, Mann JR, Stevens MC, Raafat F, Smith K: Retrospective study of prognostic value of DNA ploidy and proliferative activity in neuroblastoma. J Clin Pathol 1993, 46:1101-1104
22. Cox D, Yuncken C, Spriggs A: Minute chromatin bodies in malignant tumors of childhood. Lancet 1965, 2:55-58
23. Schwab M: Molecular cytogenetics of neuroblastoma. Biochim Biophys Acta 1992, 1114:43-50
24. Cowell JK: Double minutes and homogeneously staining regions: gene amplification in mammalian cells. Annu Rev Genet 1982, 16:21-59
25. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J: Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983, 305:245-248
26. Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, Alt FW: Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 1983, 35:359-367
27. Michitsch RW, Montgomery KT, Melera PW: Expression of the amplified domain in human neuroblastoma cells. Mol Cell Biol 1984, 4:2370-2380
28. Schwab M: Molecular genetics of human neuroblastoma. Neuroblastoma: New Approaches to Diagnosis and Therapy. Edited by M Sluyser, PA Voûte. Berlin, Springer-Verlag, 1998, pp 67-101
29. Schwab M: Amplification of N-myc as a prognostic marker for patients with neuroblastoma. Semin Cancer Biol 1993, 4:13-18
30. Christiansen H, Sahin K, Berthold F, Hero B, Terpe H-J, Lampert F: Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification, and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer 1995, 31A:541-544
31. Schwab M: Human neuroblastoma: amplification of the N-myc oncogene and loss of a putative cancer-preventing gene on chromosome 1p. Recent Res Cancer Res 1994, 135:7-16
32. Raschella G, Negroni A, Giubilei C, Romeo A, Ferrari S, Castello MA, Dominici C: Transcription of N-myc and proliferation-related genes is linked in human neuroblastoma. Cancer Lett 1991, 56:45-51
33. Wenzel A, Schwab M: The mycN/max protein complex in neuroblastoma: short review. Eur J Cancer 1995, 31A:516-519
34. Christiansen H, Lampert F: Tumour karyotype discrim- inates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 1988, 57:121-126
35. Hayashi Y, Kanda N, Inaba T, Hanada R, Nagahara N, Muchi H, Yamamoto K: Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer 1989, 63:126-132
36. Van Roy N, Cheng NC, Laureys G, Opdenakker G, Versteeg R, Speleman F: Molecular cytogenetic analysis of 1;17 translocations in neuroblastoma. Eur J Cancer 1995, 31A:530-535
37. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253:49-53
38. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR: Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 1992, 7:127-133
39. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, Pelletier J, Gros P: Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 1993, 53:5269-5273
40. Castresana JS, Bello MJ, Rey JA, Nebreda P, Queizan A, Garcia-Miguel P, Pestana A: No TP53 mutations in neuroblastoma detected by PCR-SSCP analysis. Genes Chromosomes & Cancer 1994, 10:136-138
41. Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, Westerveld A, Voûte PA, Delattre O, Laureys G, Van Roy N, Speleman F: 1p36: every band a suppressor? Eur J Cancer 1995, 31A:538-542
42. Waseem NH, Lane DP: Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA): structural conservation and the detection of a nucleolar form. J Cell Sci 1990, 96:121-129
43. Prelich G, Tan CK, Kostura M, Mathews MB, So AG, Downey KM, Stillman B: Functional identity of proliferating cell nuclear antigen and DNA polymerase-δo auxiliary protein, Nature 1987, 326:517-520
44. Bravo R, Frank R, Blundell PA, MacDonald-Bravo H: Cyclin-PCNA is the auxiliary protein of DNA polymerase-δ. Nature 1987, 326:515-517
45. Gillett CE, Barnes DM, Camplejohn RS: Comparison of three cell cycle associated antigens as markers of proliferative activity and prognosis in breast carcinoma. J Clin Pathol 1993, 46:1126-1128
46. Kreipe H, Wacker HH, Heidebrecht HJ, Haas K, Hauberg M, Tiemann M, Parwaresch R: Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol 1993, 142:1689-1694
47. Rudolph P, Lappe T, Schubert C, Schmidt D, Parwaresch RM, Christophers E: Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol 1995, 147:1615-1625
48. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715
49. Schlüter C, Duchrow M, Wohlenberg C, Becker MHG, Key G, Flad H-D, Gerdes J: The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining protein. J Cell Biol 1993, 123, 3:513-522
50. Schwarting R: Little missed markers and Ki-67. Lab Invest 1993, 68:6:597-599
51. Stout AP: Ganglioneuroma of the sympathetic system. Surg Gynecol Obstet 1947, 84:101-110
52. Schmidt D, Harms D, Carstensen S: Ganglio-neuroblastom: Diagnose und Verlauf. Verh Dtsch Ges Path 1988, 72:292-295
53. Hall PA, Levison DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990, 162:285-294
54. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991, 39:741-748
55. Linden MD, Torres FX, Kubus J, Zarbo RJ: Clinical application of morphologic and Immunocytochemical assessments of cell proliferation. Am J Clin Pathol 1992, 97:54-13
56. Taylor SR, Locker J: A comparative analysis of nuclear DNA content and N-myc gene amplification in neuroblastoma. Cancer 1990, 65:1360-1366
57. Leuschner I, Schmidt D, Schulz R, Harms D: Nerve growth factor receptor (NGFR) and ras p21 expression in neuroblastomas (NBL): correlation to NOR, grading, and prognosis. Klin Padiatr 1991, 203:332
58. Shimotake T, Iwai N, Tokiwa K, Deguchi E, Sawada T, Fushiki S: Increased numbers of argyrophilic nucleolar organizer regions between primary and metastatic sites predict tumor progression in stage IV and IV-S neuroblastoma. Cancer 1994, 73:3103-3107
59. Shimada H, Aoyama C, Chiba T, Newton WA: Prognostic subgroups for undifferentiated neuroblastoma. Hum Pathol 1985, 16:471-476
60. Baak JPA: Mitosis counting in tumors. Hum Pathol 1990, 21:683-685
61. Quinn CM, Wright NA: The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol 1990, 160:93-102
62. Schröder R, Bien K, Kott R, Meyers I, Vossing R: The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time. Acta Neuropathol Berl 1991, 82:389-394
63. van Diest PJ, Baak JP, Matze Cok P, Wisse Brekeemans EC, van Galen CM, Kurver PH, Bellot SM, Fijn- heer J, van Gorp LH, Kwee WS, Los J, Peterse JL, Ruitenberg HM, Schapers RFM, Schipper MEI, Somsen JG, Willig AWPM, Ariens AT: Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 1992, 23:603-607
64. Kamel OW, LeBrun DP, Davis RE, Berry GJ, Warnke RA: Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/cyclin 19A2. Am J Pathol 1991, 138:1471-1477
65. Coltrera MD, Gown AM: PCNA/cyclin expression and BrdU uptake define different subpopulations in different cell lines. J Histochem Cytochem 1991, 39:23-30
66. Hall PA, McKee PH, Menage HD, Dover R, Lane DP: High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993, 8:203-207
67. Prosperi E, Stivala LA, Sala E, Scovassi AI, Blanchi L: Proliferating cell nuclear antigen complex formation induced by ultraviolet irradiation in human quiescent fibroblasts as detected by immunostaining and flow cytometry. Exp Cell Res 1993, 205:320-325
68. McCormick D, Hall PA: The complexities of proliferating cell nuclear antigen. Histopathology 1992, 21:591-594
69. Key G, Becker MHG, Baron B, Duchrow M, Schlüter C, Flad H-D, Gerdes J: New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993, 68:629-636
70. Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, Liseman B, LeRiche J: Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67, J Surg Oncol 1992, 51:147-152
71. Keim DR, Hailat N, Kuick R, Reynolds CP, Brodeur GM, Seeger RC, Hanash SM: PCNA levels in neuroblastoma are increased in tumors with an amplified N-myc gene and in metastatic stage tumors. Clin Exp Metastasis 1993, 11:83-90
72. Raschella G, Romeo A, Negroni A, Pucci S, Dominick C, Castello MA, Bevilacqua P, Felsani A, Calabretta B: Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation. Cancer Res 1994, 54:2251-2255
73. McGurrin JF, Doria MIJ, Dawson PJ, Karrison T, Stein HO, Franklin WA: Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer 1987, 59:1744-1750
74. Wintzer HO, Zipfel I, Schulte Monting J, Hellerich U, von Kleist S: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991, 67:421-428
75. Sallinen P, Haapasalo H, Kerttula T, Rantala I, Kalimo H, Collan Y, Isola J, Helin H: Sources of variation in the assessment of cell proliferation using proliferating cell nuclear antigen immunohistochemistry. Anal Quant Cytoi Histol 1994, 16:261-268
76. Adam A, Hochholzer L: Ganglioneuroblastoma of the posterior mediastinum: a clinicopathologic review of 80 cases. Cancer 1981, 47:373-381
77. Lappe T, Schmidt D, Parwaresch RM, Berthold F, Harms D: Proliferationsverhalten und Prognose des Neuroblastoms. Verh Dtsch Ges Path 1994, 78:574
78. Yu CC-W, Filipe MI: Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications. Histochem J 1993, 25:843-853
79. Dervan PA, Magee HM, Buckley C, Carney DN: Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol 1992, 97:321-328
80. Bravo R, Macdonald Bravo H: Existence of two populations of cyclin/proliferating cell nuclear antigen dur- ing the cell cycle: association with DNA replication sites. J Cell Biol 1987, 105:1549-1554
81. Lopez F, Belloc F, Lacombe F, Dumain P, Feiffers J, Bernard P, Boisseau MR: The labeling of proliferating cells by Ki67 and Mib-1 antibodies depends on the binding of a nuclear protein to the DNA. Exp Cell Res 1994, 210:145-153
82. Gestblom C, Hoehner JC, Pahlman S: Proliferation and apoptosis in neuroblastoma: subdividing the mitosis-karyorrhexis index. Eur J Cancer 1995, 31A: 458-463
83. Hall PA, Coates PJ: Assessment of cell proliferation in pathology: what next? Histopathology 1995, 26:1 105-112
84. Derenzini M, Sirri V, Trere D, Ochs RL: The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest 1995, 73:497-502
85. Brugal G: Interpretation of proliferation markers. Virchows Arch 1995, 427:337-339